Laura Gilmartin Selected Research

rhuMAb-E25

1/2010

Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura Gilmartin Research Topics

Disease

2	Asthma (Bronchial Asthma) 01/2010 - 04/2007
1	Lung Injury 06/2010
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 06/2010
1	Respiratory Tract Diseases (Respiratory Tract Disease) 06/2010
1	Inflammation (Inflammations) 01/2010

Drug/Important Bio-Agent (IBA)

1	MitogensIBA 06/2010
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2010
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2010
1	ChemokinesIBA 01/2010
1	rhuMAb-E25IBA 01/2010
1	Omalizumab (Xolair)FDA Link 01/2010
1	CytokinesIBA 01/2010
1	Immunoglobulin E (IgE)IBA 01/2010
1	Histamine (Histamine Dihydrochloride)FDA Link 04/2007

Therapy/Procedure

1	Therapeutics 01/2010